Basal Insulin Titration Based on Fasting Glucose Targets

Understanding Basal Insulin Pharmacology

Glargine (Lantus) provides a relatively constant glucose‑lowering effect over 24 hours by suppressing hepatic glucose production between meals and overnight; dose adjustments should be guided by fasting glucose patterns rather than isolated bedtime readings. 1, 2

The basal insulin dose should remain unchanged despite a single bedtime glucose measurement because basal insulin is intended to control fasting plasma glucose (FPG) throughout the entire day. 1

Basal insulin titration follows an algorithm that increases the dose by 2 units every 3 days until the target FPG range (80–130 mg/dL) is achieved without causing hypoglycemia. 1, 3, 4

Fasting Morning Glucose Patterns: Evaluation of basal insulin should be based on the patient’s fasting glucose trends over several consecutive days, not on bedtime values. 1
Persistent Elevated Fasting Glucose: If the average fasting glucose consistently exceeds 130 mg/dL, increase the basal dose by 2 units every 3 days. 1, 3
Unexplained Hypoglycemia: When the patient experiences hypoglycemia without an identifiable cause, reduce the basal dose by 10–20 %. 1, 3, 4
Risk of Morning Hypoglycemia: Reducing basal insulin based on a single low bedtime reading can lead to morning hypoglycemia. 1
Avoid Confusing Basal and Correction Insulin: Basal insulin manages background glucose; correction (prandial) insulin addresses acute post‑prandial spikes. Adjustments should not conflate these two functions. 2, 5

All facts are derived from American Diabetes Association (ADA) recommendations (2025 Standards) and the cited Diabetes Care articles.

An overnight glucose nadir of approximately 96 mg/dL is above the hypoglycemia threshold of 70 mg/dL, indicating appropriate nocturnal glucose control without risk of hypoglycemia. 6

Reducing the basal insulin dose from 16 units to 12 units was appropriate, as the preceding bedtime glucose of 168 mg/dL followed by a fasting glucose of 132 mg/dL suggests over‑basalization rather than insufficient basal insulin. 7

Basal insulin adjustments should not be made in response to isolated post‑prandial hyperglycemia; instead, correction insulin or prandial agents (e.g., GLP‑1 receptor agonists) should address elevated bedtime glucose. 7

Signs of over‑basalization include a bedtime‑to‑morning glucose differential ≥50 mg/dL, unexplained hypoglycemia, or high glucose variability; none of these were observed in the current nocturnal pattern. 7